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Genome-Edited Animals Are Not Transgenic 
Animals: Moving towards Responsible Research 




In November 2018, a Chinese scientist announced that he 
was the first person to use the gene-editing technique, CRISPR-
Cas9, to create a genome-edited baby resistant to HIV, small 
pox, and malaria.1 This alarming announcement immediately 
received criticism and concern from scientists around the globe.2 
Some of them questioned the technique of applying CRISPR-
Cas9 to human embryos because of unknown gene-editing risks.3 
For example, knocking out the gene that controls HIV might 
render a person susceptible for West Nile Virus.4 Some other 
scientists challenged the ethical implications of this move to 
produce “designer babies.”5 Marcy Darnovsky, executive director 
of the Center for Genetics and Society, lamented that “this 
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 1. See Rob Stein, Chinese Scientist Says He’s First to Create Genetically 
Modified Babies Using CRISPR, NPR (Nov. 26, 2018, 5:02 AM), 
https://www.npr.org/sections/health-shots/2018/11/26/670752865/chinese-
scientist-says-hes-first-to-genetically-edit-babies. 
 2. See, e.g., Antonio Regalado, Chinese Scientists Are Creating CRISPR 
Babies, MIT TECH. REV. (Nov. 25, 2018), 
https://www.technologyreview.com/s/612458/exclusive-chinese-scientists-are-
creating-crispr-babies/ (noting that some scientists called the undertaking 
cause for “regret and concern over the fact that gene editing—a powerful and 
useful technique—was put to use in a setting where it was unnecessary.”). 
 3. See Stein, supra note 11 (noting that applying CRISPR-Cas9 to 
embryos might introduce unknown, new diseases that could be passed down for 
generations). 
 4. See id. 
 5. See id. 
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amounts to unethical and reckless experimentation on human 
beings, and a grave abuse of human rights.”6 
CRISPR-Cas9 is a groundbreaking gene-editing technology 
that enables scientists to make precise changes in DNA more 
easily, quickly, and economically.7 Scientists can now insert or 
delete certain genes at a specific site with the aid of CRISPR-
Cas9.8 As a result, this technology raises high hopes among 
scientists for major breakthroughs in all applications.9 
Meanwhile, the government and other experts assert that the 
current regulatory landscape in the United States over genome-
edited products with new biotechnologies like CRISPR-Cas9—
the Coordinated Framework for the Regulation of 
Biotechnology—may be inadequate to manage the risks 
associated with gene-editing techniques and their impacts on the 
environment and human health because existing regulations 
cannot keep up with the rapidly growing biotechnologies.10 
Although the public does not yet need to be concerned with 
the application of CRISPR-like techniques on human embryos in 
the United States,11 they will likely see CRISPR-edited food on 
                                                        
 6. Press Release, Ctr. for Genetics & Soc’y, Claim of Genetically Modified 
Babies: If True, a Grave Abuse of Human Rights (No v. 26, 2018), 
https://www.geneticsandsociety.org/press-statement/claim-genetically-
modified-babies-if-true-grave-abuse-human-rights. 
 7. See Henry T. Greely, Are We Ready for Genetically Modified Animals, 
WORLD ECON. FORUM (Jan. 19, 2016), 
https://www.weforum.org/agenda/2016/01/are-we-ready-for-genetically-
modified-animals/. Though this Note primarily focuses on CRISPR-Cas9, the 
discussion also applies to other CRISPR-like gene-editing technologies such as 
ZFNs and TALENs. See Daniel F. Voytas & Caixia Gao, Precision Genome 
Engineering and Agriculture: Opportunities and Regulatory Challenges, 12 
PLOS BIOLOGY 1, 2 (2014). 
 8. See Tracey Tomlinson, A CRISPR Future for Gene-Editing Regulation: 
A Proposal for an Updated Biotechnology Regulatory System in an Era of 
Human Genomic Editing, 87 FORDHAM L. REV. 437, 445–46 (2018). 
 9. See Stein, supra note 1. 
 10. See generally MARCY E. GALLO ET AL., ADVANCED GENE EDITING: 
CRISPR-CAS9 (2018) (finding that “[r]egulatory gaps may lead to increased 
uncertainty that could slow down the development of future biotechnology 
products or result in a loss of public confidence in regulators.”). 
 11. See Julia Belluz, How Soon Will CRISPR Gene-edited Babies Come to 
the US? VOX (Dec. 6, 2018), https://www.vox.com/science-and-
health/2018/12/6/18126338/crispr-babies-china-gene-editing (noting that 
genetically-modified embryos are prohibited in the U.S. and offenders might 
face jail time and a $100,000 fine). 
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their plates in the very near future.12 The first of these genome-
edited crops—Cibus Canola—went on the market in 2018,13 with 
more coming such as TALEN-edited soybeans that contain no 
trans fats.14 Though genome-edited animals have not yet been 
approved for human consumption, a transgenic salmon—
AquAdvantage Salmon—using the recombinant DNA 
technology has already been approved by the Food and Drug 
Administration (FDA).15 Some scientists and environmental 
groups have raised ethical questions about the unintended 
ecological consequences of introducing a genetically modified 
organism into an open environment.16 
Traditionally, the FDA has regulated genetically engineered 
animals for consumption under the new animal drug provisions 
of the Federal Food, Drug and Cosmetic Act (FD&C Act).17 With 
its pronouncement of guidance #187 on intentionally altered 
genomic DNAs in 2017, the FDA also indicates that it inclines to 
regulate genome-edited animals with CRISPR-like technologies 
                                                        
 12. See Michael Le Page, The Second Great Food War: Battle Lines Are 
Being Drawn Over Whether Crops and Animals Modified with CRISPR Gene 
Editing Can Make It onto Supermarket Shelves, 239 NEW SCIENTIST 22 (2018) 
(“What we eat could be about to undergo a big change.”). 
 13. See Frank Vinluan, Cibus Raises $70M for Marketing of Gene-edited 
Canola, More R&D, XCONOMY (June 27, 2018), https://xconomy.com/san-
diego/2018/06/27/cibus-raises-70m-for-marketing-of-gene-edited-canola-more-
rd/ (reporting that sales of Cibus’ gene-edited canola went up). 
 14. See Caitlin Dewey, The Future of Food: Scientists Have Found a Fast 




 15. See generally U.S. FOOD & DRUG ADMIN., AN OVERVIEW OF ATLANTIC 
SALMON, ITS NATURAL HISTORY, AQUACULTURE, AND GENETIC ENGINEERING 





m] [hereinafter USDA]. 
 16. See Ocean Conservancy, et al., Citizen Petition Regarding AquaBounty 
Technologies’ Application for Approval of Genetically Engineered Salmon (May 
25, 2011), https://www.regulations.gov/document?D=FDA-2011-P-0448-0001. 
 17. In this Note, “genetically engineered animal” is a catchall phrase that 
refers to animals modified by rDNA techniques or other methods involving 
inserting DNA from one organism’s genome into another organism’s cell directly 
without any precise modification. See Guidance for Industry on Regulation of 
Genetically Engineered Animals Containing Heritable recombinant DNA 
Constructs, 74 FED. REG. 3057, 3057 (Jan. 16, 2009). 
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under the same provisions.18 Yet, this guidance was not well 
received by various stakeholders.19 Scientists and developers 
worry that the FDA’s interpretation of altered genomic DNAs as 
animal drugs can stunt innovation of biotechnologies that will 
bring numerous benefits to the society.20 In the meantime, 
nonprofits and other organizations disagree with the FDA’s 
approach to treating genome-edited animals the same as 
transgenic animals, when in fact they pose different levels of 
risk.21 
Therefore, the questions for this Note are whether the FDA’s 
updated draft #187 provides legally sound mechanism for agency 
oversight of genome-edited animals and whether other 
regulatory pathways exist for agency oversight of genome-edited 
animals with new CRISPR-like biotechnologies under the 
current regulatory framework. Part I explains CRISPR-Cas9 
and other precision gene-editing technologies, the history of the 
application of biotechnology on animals and the current 
development of genome-edited animals, U.S. regulatory 
framework on biotechnology, and the FDA’s draft guidance #187. 
Part II discusses how the FDA’s interpretation of altered 
genomic DNAs as animal drugs has exceeded its vested 
authority by Congress under existing statutes, how the FDA’s 
approach deviates from the product-oriented regulatory 
approach, and how the FDA’s issuance of the guidance document 
is inadequate to address biotechnology products that affect the 
environment and human health. Part III explores alternative 
                                                        
 18. See Regulation of Intentionally Altered Genomic DNA in Animals Draft 
Guidance, 82 FED. REG. 6561 (Jan. 19, 2017). 
 19. Cf., e.g., Consumers Union, Comment Letter on the Food and Drug 
Administration’s Draft Guidance for Industry #187 “Regulation of Intentionally 
Altered Genomic DNA in Animals” (June 19, 2017), 
https://www.regulations.gov/document?D=FDA-2008-D-0394-0431. 
 20. See, e.g., Info. Tech. & Innovation Found., Comment Letter on the Food 
and Drug Administration’s Draft Guidance for Industry #187 “Regulation of 
Intentionally Altered Genomic DNA in Animals” (Apr. 11, 2017), 
https://www.regulations.gov/document?D=FDA-2008-D-0394-0331. 
 21. See, e.g., Ctr. for Food Safety, Comment Letter on The Food and Drug 
Administration’s Draft Guidance for Industry #187 “Regulation of Intentionally 
Altered Genomic DNA in Animals” (June 19, 2017), 
https://www.regulations.gov/document?D=FDA-2008-D-0394-0427; see also 
Nat’l Ass’n of St. Dep’t of Agric., Comment Letter on the Food and Drug 
Administration’s Draft Guidance for Industry #187 “Regulation of Intentionally 
Altered Genomic DNA in Animals” (June 19, 2017), 
https://www.regulations.gov/document?D=FDA-2008-D-0394-0409. 
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pathways for agency oversight of genome-edited animals under 
the existing statutes and proposes that the White House updates 
the Coordinated Framework to incorporate the Responsible 
Research and Innovation (RRI) principle so as to address the risk 
of new biotechnological products while fostering public welfare-
oriented responsible innovation with societal acceptability. 
Notably, in focusing on the FDA’s draft guidance to regulate 
intentionally altered genomic DNA, this Note is not intended to 
disrespect the FDA and its approach to protect the public health 
and food safety. Instead, this Note, using the FDA’s guidance as 
an illustration, highlights the shortfalls of the current 
regulatory framework and its inability to adapt to the disruptive 
nature of technological development. In an environment of what 
some regulation scholars call “global innovation arbitrage,”22 the 
answer to the “what is the right regulatory approach?” question 
is key to keep the U.S. competitive in biotechnological innovation 
while protecting citizens and human interest. 
I. BACKGROUND 
This Part of the Note provides background information on 
CRISPR-Cas9 as an illustration of precision gene-editing 
technologies, a brief survey of the development of animal 
biotechnologies, current regulatory structures for biotechnology 
in the United States, particularly the existing regulations over 
genetically engineered animals, and the FDA’s attempt to cover 
genome-edited animals under the existing statutes through 
guidance #187. The background information of Part I will 
facilitate an understanding of the technical analysis of guidance 
#187 and shed light on reasons as to why the current regulatory 
framework cannot keep up with disruptive technologies like 
CRISPR-Cas9 which would be discussed later in detail. 
A. WHAT IS CRISPR? 
CRISPR, an acronym for Clustered Regularly Interspaced 
Short Palindromic Repeat, is an “organization of short, partially 
                                                        
 22. See Adam Thierer, Global Innovation Arbitrage: Export Controls 
Edition, THE TECH. LIBERATION FRONT (Jan. 2, 2019), 
https://techliberation.com/2019/01/02/global-innovation-arbitrage-export-
controls-edition/ (defining global innovation arbitrage as the “idea that 
innovators can, and will with increasingly regularity, move to those 
jurisdictions that provide a legal and regulatory environment more hospitable 
to entrepreneurial activity.”). 
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palindromic repeated DNA sequences” naturally found in 
bacteria.23 First discovered in 1987, CRISPR was shown to be a 
successful bacterial defense mechanism against viruses twenty 
years later.24 CRISPR is made up of two parts: repeats that are 
short sequences of DNA, and unidentical spacers that connect 
these repeats.25 Also found within the bacterium are CRISPR-
associated genes, known as Cas genes, which make Cas9 
proteins that are able to unwind and cleave DNA.26 
When a virus attacks a bacterial cell, some segments of the 
viral DNA will be copied and inserted as a new spacer into the 
existing bacterial CRISPR sequences.27 Immediately, the 
CRISPR sequences that includes this new spacer from the viral 
DNA undergo a process of transcription—copying the double-
chain helix structured DNA into a single-chain RNA.28 The short 
segments of this long RNA transcribed from the original 
CRISPR sequences are CRISPR RNAs (crRNAs).29 Should the 
same virus attack again, the Cas genes will be triggered to create 
Cas9 proteins. Then, the crRNAs will guide these Cas9 proteins 
to the invading virus because the crRNAs, with copies of the 
corresponding viral DNA, are able to match the viral genome.30 
These Cas9 proteins will then destroy the viral genome by 
unwinding its DNA and cutting up any DNA sequence that 
matches the crRNA sequence.31 
In the field of genome editing, CRISPR refers to one of the 
many gene-editing technologies that enable scientists to make 
precise cuts along a cell’s genome.32 The CRISPR system consists 
                                                        
 23. See Ekaterina Pak, CRISPR: A Game-Changing Genetic Engineering 
Technique, HARV. U. GRADUATE SCH. OF ARTS & SCI. (July 31, 2014), 
http://sitn.hms.harvard.edu/flash/2014/crispr-a-game-changing-genetic-
engineering-technique/. 
 24.  24. See generally GALLO ET AL., supra note 10, at 32 (2017) 
(providing a chronology of discoveries and milestones in the development of 
CRISPR-Cas9). 
 25. See Bozeman Science, What Is CRISPR?, YOUTUBE (Feb. 18, 2016), 
https://www.youtube.com/watch?v=MnYppmstxIs. 
 26. See id. Cas proteins convert chemical energy into mechanical forces in 
response to specific stimuli. Pak, supra note 23. 
 27. See Pak, supra note 23. 
 28. See id. 
 29. See id. 
 30. See Bozeman Science, supra note 25. 
 31. See id. 
 32. See Tomlinson, supra note 8, at 443 (“CRISPR is used as a catchall term 
for systems that enable researchers to program the CRISPR molecule to make 
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of two components: the Cas9 protein and a guide RNA that can 
recognize the sequence of DNA to be edited.33 Scientists are able 
to create guide RNAs that match specific DNA sequences to be 
edited in a cell, just like how CRISPR in a bacterium generates 
crRNAs.34 Scientists then attach these artificially created guide 
RNAs to the DNA-cutting protein Cas9 and introduce this 
complex into the target cell.35 The guide RNAs will direct the 
enzyme Cas9 to the targeting DNA sequence at a specific site, 
allowing it to unwind the double helixes and subsequently 
matching to the single-stranded DNA sequence.36 When the 
match completes, Cas9 will cut the targeted DNA sequence; once 
the host DNA is broken, the gene will be successfully inactivated 
or deleted.37 Scientists can also add a new RNA sequence to 
where the host DNA is cut; by doing this, they successfully add 
genetic material to the target cell.38 After these intentional edits, 
scientists rely on a cell’s own ability to repair its DNA 
sequence.39 With the CRISPR-Cas9 system, scientists can finally 
edit the existing genome by deleting or inserting DNA sequences 
at a precise location.40 
                                                        
precise cuts along a cell’s genome.”). See Voytas & Gao, supra note 7, at 2 
(introducing other types of genome-editing technologies that are similar to 
CRISPR which include engineered homing endonucleases or meganucleases, 
zinc finger nucleases (ZFNs), and transcription activator-like effector nucleases 
(TALENs)). 
 33. See GALLO ET AL., supra note 10, at 2–3 (explaining how the CRISPR-
Cas9 system functions). 
 34. See id. 
 35. See id. 
 36. See id. 
 37. See Evita V. Grant, FDA Regulation of Clinical Applications of 
CRISPR-CAS Gene-Editing Technology, 71 FOOD & DRUG L.J. 608, 611 (2016) 
(explaining that the CRISPR-Cas system can “recognize and cleave a specific 
sequence of DNA, allow[ing] it to be developed into artificial restriction enzymes 
that can be used to alter specific sites of DNA in any organism.”). 
 38. See id. 
 39. See U.C. BERKELEY, DNA Repair After CRISPR Cutting Not at All What 
People Think, PHYS.ORG (Jul. 30, 2018), https://phys.org/news/2018-07-dna-
crispr-people-thought.html (explaining two types of repair: non-homologous 
end-joining repair and homology-directed repair). 
 40. See Tomlinson, supra note 8, at 445–46 (claiming that CRISPR is the 
“most advanced gene-editing technology currently available” that enables 
“scientists to edit the human genome in previously impossible ways.”). 
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B. CRISPR-LIKE TECHNOLOGIES ARE DIFFERENT FROM 
TRANSGENESIS TECHNIQUES 
This newly evolved CRISPR-Cas9 system, along with other 
gene-editing technologies,41 differs from transgenesis which 
directly inserts a copy of genetic material with a specific trait 
from a donor organism into a cell of a recipient organism.42 
Transgenesis, however, does not control the site in the genome 
where the inserted material will end up and can result in 
random consequences.43 Unlike traditional genetic engineering 
with transgenic techniques, scientists can precisely edit a single 
sequence of the genome at a very specific site with CRISPR-
Cas9.44 Thus, CRISPR-Cas9 is at least 10 times more accurate 
and predictable.45 It can also democratize biotechnology because 
anyone with basic knowledge and skills in molecular biology can, 
theoretically, perform a CRISPR cutting.46 
Furthermore, CRISPR-Cas9 is often viewed less as an 
artificial process but a mechanism “mimicking a natural 
mutation.”47 This is because gene-editing does not require the 
transfer of DNA from one organism to another but capitalizes on 
a cell’s natural defense mechanism to induce “a specific change 
                                                        
 41. See Voytas & Gao, supra note 32 and accompanying text. 
 42. See Leslie Pray, Recombinant DNA Technology and Transgenic 
Animals, 1 NATURE EDUC. 51 (2008) (discussing inserting foreign DNA into a 
new host cell). 
 43. See GMO Answers, How Are GMOs Created? | The Hawaiian Rainbow 
Papaya Story, YOUTUBE (Aug. 2, 2013), https://www.youtube.com/watch?v=2G-
yUuiqIZ0&t=234s. 
 44. See Ken Kingery, What Is CRISPR, and How Has It Changed Genetic 
Research?, WORLD ECON. FORUM (Oct. 30, 2015), 
https://www.weforum.org/agenda/2015/10/what-is-crispr-and-how-has-it-
changed-genetic-research/ (“The primary advantage of CRISPR over previous 
technologies is the ability to use a genetic scalpel rather than a 
sledgehammer[.]”); see also Greg Licholai, Is CRISPR Worth the Risk?, YALE 
INSIGHTS (Aug. 21, 2018), https://insights.som.yale.edu/insights/is-crispr-
worth-the-risk (“What was previously attempted with gene editing was . . . kind 
of like trying to edit a book by only being able to rip out a page at a time and 
transfer a page at a time . . . . [T]his technology . . . literally comes down to the 
individual letters.”). 
 45. See Greely, supra note 7 (“DNA editing had been done in laboratories 
for about 40 years, but CRISPR/Cas9 is at least 10 times more accurate, faster, 
easier and less expensive.”). 
 46. See Grant, supra note 37, at 626–27 (describing CRISPR as accessible, 
easy to use and affordable). 
 47. Ann Bruce, Genome Edited Animals: Learning from GM Crops?, 26 
TRANSGENIC RES. 385, 389 (2017). 
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at a precise location in the genome.”48 Despite their accuracy and 
accessibility, CRISPR-like technologies could potentially result 
in off-target effects when the Cas9 enzyme snips at similar non-
target sites.49 Scientists have developed various strategies to 
contain such effects.50 This Note, however, will not go into 
details discussing various shortfalls of CRISPR-like technologies 
and how scientists have adopted measures to tackle these 
problems.51 
C. HISTORICAL OVERVIEW OF GENETICALLY ENGINEERED 
ANIMALS BEFORE CRISPR-LIKE TECHNOLOGIES 
Looking back at the development of biotechnology, it is not 
hard to find the application of biotechnology on animals; in fact, 
animal biotechnology has been around for centuries.52 Before the 
late nineteenth century, human-directed breeding was the 
dominant method for the selection of animals that match 
particular production traits and purposes suited to a specific 
climate.53 In the next fifty years, the farm animal industry 
witnessed a growing array of reproductive biotechnologies, such 
                                                        
 48. See id. at 391 (arguing that “genome editing does not transgress species 
barriers” but does “require a deliberate intervention that is outside natural 
mutation.”). 
 49. See generally Ellen Shrock & Marc Güell, CRISPR in Animals and 
Animal Models, in 152 PROGRESS IN MOLECULAR BIOLOGY AND TRANSLATIONAL 
SCIENCE 1, 97 (Raúl Torres-Ruiz & Sandra Rodriguez-Perales eds., 2017) 
(discussing that off-target effects might cause chromosomal deletions, 
inversions, or translocations). 
 50. See Wenfang Tan, et al., Gene Targeting, Genome Editing: From Dolly 
to Editors, 25 TRANSGENIC RES. 273, 283 (2016) (providing examples to control 
off-site effects such as masking Cas9 with a fusion peptide, preventing activity 
until cleaved by a small molecule, expanding the TALEN RDV repertoire, 
dimerizing the editing enzyme, etc.). 
 51. Excellent articles in the last few years have detailed the shortfalls of 
CRISPR-Cas9. See Michael Kosicki, Kärt Tomberg & Allan Bradley, Repair of 
Double-Strand Breaks Induced by CRISPR-Cas9 Leads to Large Deletions and 
Complex Rearrangements, 36 NATURE BIOTECHNOLOGY 765 (2018); see also 
Heidi Ledford, CRISPR Gene Editing Produces Unwanted DNA Deletions, 
NATURE (Jul. 16, 2018), https://www.nature.com/articles/d41586-018-05736-3. 
 52. See Heiner Niemann & Bob Seamark, The Evolution of Farm Animal 
Biotechnology, in ANIMAL BIOTECHNOLOGY 1: REPRODUCTIVE 
BIOTECHNOLOGIES 1, 1–8 (Heiner Niemann & Christine Wrenzycki eds., 2018) 
(discussing “Domestication”, “Systematic Breeding”, and “Scientifically-based 
Breeding” as forms of animal biotechnology). 
 53. See id. at 3 (“[H]uman-directed breeding results in the abundance of 
great phenotypic and genetic variation in domesticated animals including, for 
example, the more than 3,000 cattle and 1,300 pig breeds”). 
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as artificial insemination.54 Artificial insemination has replaced 
traditional breeding methods for breeders and “remain[ed] the 
primary method . . . around the globe [] to improve the genetic 
quality of their animals . . . .”55 
In the next twenty years, researchers have applied this 
DNA analysis to animal breeding, using quantitative trait loci 
(QTL) to identify causal mutations for specific traits.56 Soon, a 
new era in animal breeding began with the creation of the first 
transgenic pigs and sheep.57 Transgenesis can be achieved by 
microinjection of a foreign DNA into an oocyte—an immature 
egg cell of the animal ovary—shortly after fertilization.58 
Transgenesis, nevertheless, faced a few limitations, the primary 
one being that the introduced DNA could only be integrated 
randomly in the recipient genome.59 As of today, there is already 
                                                        
 54. See id. at 5 (showcasing that under these emerging reproductive 
biotechnologies, genetics has been applied to animal breeding, which has helped 
identify inheritable chemical or molecular markers that could be used to guide 
breeding technologies and promote genetic change in economically important 
productive traits). 
 55. See id. at 10 (“[Artificial Insemination] is employed in more than 90% 
of all sexually mature female dairy cattle in countries with well-advanced 
breeding programs . . . . [t]he adoption of [artificial insemination] for use with 
low unit cost animals such as sheep and goats is less widespread but is still 
employed in the breeding of greater than 3.3 million sheep and 0.5 million goats 
annually”). 
 56. See id. at 7–8 (finding that the QTL strategy was succeeded by marker-
assisted selection which includes the detection of several QTLs, followed by 
identification of the gene which causes the respective mutation and finally the 
increase of the frequency of the favorable allele by selection). 
 57. See Niemann & Seamark, supra note 52, at 19 (“[I]ntroducing new and 
functional genetic material into the germline of laboratory rodents heralded a 
new era in animal breeding.”). See generally Götz Laible, Production of 
Transgenic Livestock: Overview of Transgenic Technologies, in ANIMAL 
TECHNOLOGY 2: EMERGING BREEDING TECHNOLOGIES 95, 95–113 (Heiner 
Niemann & Christine Wrenzycki eds., 2018) (discussing transgenic livestock). 
 58. See Laible, supra note 57, 95–113 (introducing two types of transgenic 
technologies: the embryo-mediated approach refers to the introduction of the 
genetic modification into an embryo whereas the cell-mediated approach refers 
to the introduction of genetic information into a cell which “is subsequently used 
to generate an entire animal based on the genetics of this cell.”). 
 59. Niemann & Seamark, supra note 52, at 19. See Laible, supra note 57, 
at 101–02 (finding that “only 70% of transgenic founder animals were able to 
transmit the transgene through the germline to the next generation” and that 
the process is inefficient and very expensive). 
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one transgenic animal approved for human consumption in the 
United States—AquAdvantage Salmon.60 
D. EMERGING APPLICATIONS OF CRISPR-LIKE TECHNOLOGIES 
ON ANIMALS 
The CRISPR-Cas9 system has overcome the many 
limitations transgenesis faced and has been used to create a 
wide variety of genome-edited animals, such as pigs, cattle, 
goats, and sheep.61 Unlike transgenesis which might lead to 
random consequences from the combination of the donor 
organism’s DNA with the recipient organism’s cell, CRISPR-
Cas9 is able to edit an animal’s genome in a precise manner to 
obtain a targeted trait.62 Consequently, genome-edited animals 
created from CRISPR-like technologies play an important role in 
“highly diverse areas such as food improvement, disease 
resistance, and human disease models.”63 For instance, 
AgGenetics has engineered Angus cows to produce a certain type 
of hair that will allow them to adapt to warmer climates and 
thus increase Angus beef’s yields.64 Recombinetics has also gene-
edited a hornless breed of cattle, freeing it from using hot irons 
to burn off horns during food processing and significantly 
improving animal welfare.65 Moreover, CRISPR-Cas9 has also 
                                                        
 60. See Heidi Ledford, Transgenic Salmon Leaps to the Dinner Table, 527 
NATURE 417 (2015). See generally, USDA, supra note 15 (illustrating that 
AquAdvantage fish produce extra growth hormone which allows them to grow 
to market size in eighteen months rather than the usual three years). 
 61. See generally Shrock & Güell, supra note 49, at 98–105 (outlining three 
methods of using the CRISPR-Cas9 system on animals); Tan, supra note 50, at 
277 (listing all genome-edited animals in a table); see Gavin J. Knott & Jennifer 
A. Doudna, CRISPR-Cas Guides the Future of Genetic Engineering, 361 SCI. 
866, 867 (2018) (discussing applications of CRISPR to biomedical and clinical 
research, such as engineering T cells as a prelude to developing advanced 
immunotherapies to target cancers and targeting the genetic basis for sickle cell 
disease); see GALLO, supra note 24, at 20 (explaining that CRISPR has also been 
widely applied to agricultural development, such as better plant-pest control, 
new and enhanced nutritional characteristics, and plant varieties that could be 
grown on marginal lands or in poor quality soils). 
 62. See supra Section I.B. 
 63. Bjoern Petersen, DNA Nucleases and their Use in Livestock Production, 
in ANIMAL BIOTECHNOLOGY 2: REPRODUCTIVE BIOTECHNOLOGIES 123, 124 
(Heiner Niemann & Christine Wrenzycki eds., 2018). 
 64. See Shrock & Güell, supra note 49, at 104. 
 65. See id. (providing additional examples such as genetically modified 
chickens which produce non-allergen eggs, pigs resistant to the Porcine 
Reproductive and Respiratory Syndrome Virus, and cattle are resistant to 
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been used to produce genome-edited pets that contain custom 
traits.66 Overall, CRISPR-Cas9 has significantly accelerated the 
creation of animals with novel traits that may be beneficial for 
agricultural production and animal health.67 
E. CURRENT REGULATORY FRAMEWORK FOR BIOTECHNOLOGY 
IN THE U.S. 
The federal government has a long history of regulating 
biotechnology. It first came up with a set of research guidelines 
in the 1970s in response to the emerging recombinant DNA 
research for transgenesis technologies.68 In the next eight years, 
Congress made many attempts to enact a unified biotechnology 
legislation to address the emerging genetic manipulation 
techniques.69 In 1984, the White House Cabinet Council on 
                                                        
bovine tuberculosis). See generally Adam Shriver & Emilie McConnachie, 
Genetically Modifying Livestock for Improved Welfare: A Path Forward, 31 J. 
AGRIC. ENV’T ETHICS 161 (2018) (arguing that modern biotechnologies improve 
animal welfare). 
 66. See Shrock & Güell, supra note 49, at 105 (providing examples of very 
small pigs as pets and dogs with improved running ability). 
 67. See, e.g., id. at 101 (“The uses of CRISPR–Cas9 for animal genome 
engineering include . . . the inactivation or alteration of genes in model animals 
in order to elucidate the functions of these genes . . . the production of animal 
models of human disease to study disease progression in a controlled manner 
and evaluate potential therapies . . . and the use of genetically modified animals 
for industrial, pharmaceutical, and biotechnological production”); Bruce, supra 
note 47, at 387–88; Zahra Meghani & Jennifer Kuzma, Regulating Animals with 
Gene Drive Systems: Lessons from the Regulatory Assessment of a Genetically 
Engineered Mosquito, 5 J. RESPONSIBLE INNOVATION 203 (2018) (discussing 
gene drives); George Washington University Regulatory Studies Center, 
Comment Letter on The Food and Drug Administration’s Draft Guidance for 
Industry #187 “Regulation of Intentionally Altered Genomic DNA in Animals” 
(June 19, 2017), https://www.regulations.gov/document?D=FDA-2008-D-0394-
0416 (listing CRISPR projects that involve resurrecting lost species, protecting 
extremely endangered species, increasing agricultural productivity and 
controlling human disease dependent on wild animal hosts); Veronique 
Greenwood, How CRISPR Is Spreading Through the Animal Kingdom, 
PBS.ORG (May 23, 2018), https://www.pbs.org/wgbh/nova/article/crispr-
animals/. 
 68. See NAT’L ACAD. OF SCI., ENG’G, AND MED., PREPARING FOR FUTURE 
PRODUCTS OF BIOTECHNOLOGY 69 (2017) (explaining that the National 
Institutes of Health published a set of research guidelines in 1976 as the 
prototype of the federal regulatory framework, applied to all research with 
recombinant or synthetic nucleic acid molecules). 
 69. See WHITE HOUSE, MODERNIZING THE REGULATORY SYSTEM FOR 
BIOTECHNOLOGY PRODUCTS: FINAL VERSION OF THE 2017 UPDATE TO THE 
COORDINATED FRAMEWORK FOR THE REGULATION OF BIOTECHNOLOGY 3 (2017) 
(explaining that enhanced characteristics of food, manufactured food, waste 
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Natural Resources and the Environment formed a working 
group on biotechnology which proposed a coordinated framework 
to address products developed from new technologies.70 
In 1986, the White House issued the nation’s first regulatory 
document about genetically engineered products, Coordinated 
Framework on the Regulation of Biotechnology (Coordinated 
Framework), which clarified the regulatory authority and 
responsibility of each federal agency regarding products derived 
from new biotechnologies.71 The framework identified a lead 
agency among the agencies responsible for regulation of a 
specific product category or use: the FDA regulates the safety of 
all food and cosmetic products sold for human use; the 
Department of Agriculture (USDA) regulates the production and 
marketing of products grown on farms; and the Environment 
Protection Agency (EPA) regulates actual and potential threats 
to human health resulting from disruption of the environment.72 
The Coordinated Framework also established three 
essential tenets: (1) U.S. regulatory policy over biotechnological 
products would be product-based instead of process-based;73 (2) 
only regulation grounded in verifiable scientific risks would be 
tolerated;74 (3) existing statutes are sufficient to review new 
products, meaning that statutes enacted before this framework 
                                                        
disposal, medicine and pesticides rely upon new techniques such as 
recombinant DNA, recombinant RNA, and cell fusion). 
 70. See id. at 70 (orchestrating the biotechnology-related responsibilities of 
multiple federal agencies). 
 71. Executive Office of the President, Coordinated Framework for 
Regulation of Biotechnology, 51 FED. REG. 23302, at 23303 (June 26, 1986). 
 72. WHITE HOUSE, supra note 69, at 28 n.77; Edward L. Rubin & Joanna 
K. Sax, Administrative Guidance and Genetically Modified Food, 60 ARIZ. L. 
REV. 539, 554 (2018). 
 73. See Zahra Meghani, Genetically Engineered Animals, Drugs, and 
Neoliberalism: The Need for a New Biotechnology Regulatory Policy Framework, 
30 J. AGRIC. ENV’T ETHICS 715, 733 (2017) (“Regulation by the FDA must be 
based on the rational and scientific evaluation of products, and not on a priori 
assumptions about certain processes.”); Rubin & Sax, supra note 72, at 555 
(focusing on the characteristics and risk posed by the introduction, rather than 
on the process by which a product is created). 
 74. Eric E. Williams, CRISPR: Redefining GMOs—One Edit at a Time, 39 
U. ARK. LITTLE ROCK L. REV. 437, 451 (2017). See generally NAT’L ACAD. OF SCI., 
ENG’G, AND MED., supra note 68, at 69 (“Regulatory risk 
assessment . . . [identifies] possible causes of harm . . . the relationship between 
exposure to the harm and the probability of the adverse effect . . . the extent of 
human or environmental exposure to the harm, and . . . the probability of the 
harm occurring and the magnitude of the possible harm[.]”). 
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were interpreted to cover biotechnology.75 Under this 
framework, the federal government sought to “achieve a balance 
between regulation adequate to ensure the protection of health 
and the environment while maintaining sufficient regulatory 
flexibility to avoid impeding innovation.”76 In 1992, the 
Coordinated Framework was updated to reaffirm a scientific, 
risk-based, and product-based approach consistent with the 
1986 Coordinated Framework.77 
Almost twenty years later, the White House updated the 
Coordinated Framework in 2017 in response to the accelerating 
development and application of precise gene-editing 
biotechnologies.78 In the past decade, there were growing 
concerns regarding whether products developed using new 
technologies such as CRISPR-Cas9 would fall outside the scope 
of existing regulations and what factors should be considered to 
assess risks.79 Thus, the 2017 update attempted to clarify: (1) 
what biotechnology product areas are regulated; (2) what roles 
each agency plays for different product areas; (3) how agencies 
communicate and coordinate with each other; and (4) what 
reviewing and updating mechanism each agency should adopt.80 
This update reaffirmed the tenets established under the 1986 
Coordinated Framework that regulations should be product-
                                                        
 75. See Meghani, supra note 73, at 733 (arguing that the working group 
chose existing statutes because of the considerations of “immediate regulatory 
protection and certainty” for the biotechnology companies which the state 
believed to be in the interest of the U.S. on the global arena). 
 76. WHITE HOUSE, supra note 69, at 4. 
 77. Meghani, supra note 73, at 735–37. See NAT’L ACAD. OF SCI., ENG’G, 
AND MED., supra note 68, at 70 (evaluating the risk-based assessment based on 
the characteristics of the organism, the target environment, and the type of 
application). 
 78. WHITE HOUSE, supra note 69. See NAT’L ACAD. OF SCI., ENG’G, AND 
MED., supra note 68, at 70 (providing a basic survey of statutory authorities of 
the EPA, the FDA, and the USDA to regulate environmental and human health 
and safety risks related to biotechnology products). 
 79. See Emily Waltz, A Face-lift for Biotech Rules Begin, 33 NATURE 
BIOTECH., 1221 (2015) (explaining contexts for the 2017 update); Kelly Servick, 
U.S. to Review Agricultural Biotech Regulations, 349 SCI. 131 (2015) (finding 
the outdated framework has resulted in puzzling regulatory paths and a new 
framework would help clarify each agency’s role and strategy); see Heidi 
Ledford, Gene-editing Surges as US Rethinks Regulations, NATURE (Apr. 12, 
2016), https://www.nature.com/news/gene-editing-surges-as-us-rethinks-
regulations-1.19724 (considering that gene-edited products would fall outside 
the scope of existing regulation). 
 80. WHITE HOUSE, supra note 69, at 1–2. 
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based,81 the regulatory system should be grounded in risk 
assessment,82 and existing statutory authorities of each agency 
are sufficient to cover biotechnology products and their 
applications.83 Importantly, the update ceased to identify lead 
agencies which had caused confusion and been mistakenly 
interpreted; instead it encouraged coordination and 
communication among agencies and clarified “current 
responsibilities and the relevant coordination across [the] EPA, 
[the] FDA, and [the] USDA for the regulatory oversight of 
[different] biotechnology products.”84 With such an upgrade in 
the federal biotechnology regulatory system, the federal 
government believed that it would “increase public confidence in 
the regulatory system and prevent unnecessary barriers to 
future innovation and competitiveness.”85 
Despite the federal government’s attempt to clarify the roles 
of each agency, the 2017 update still left each agency with 
significant flexibility to determine whether it has regulatory 
authority over certain genome-edited products under existing 
statutes. Guided by the updated Coordinated Framework, the 
agencies have made respective changes to their regulation of 
genome-edited products.86 For example, the FDA has read the 
existing statutes to cover genome-edited animals whereas the 
USDA has proactively excluded certain genome-edited 
organisms that are modified solely by genetic deletions from its 
regulatory review.87 Even though the Coordinated Framework 
confers considerable flexibility to the agencies, existing statutes 
                                                        
 81. Id. at 8 (“Exercise of agency oversight within the scope afforded by 
statutes should be commensurate with the risk posed by the introduction of the 
biotechnology product and should not turn on the fact that it was created or has 
been altered by a particular process or technique.”). 
 82. Id. at 7 (“It is the characteristics of the biotechnology product, the 
environment into which it will be introduced, and the application of the product 
that determine its risk (or lack thereof).”). 
 83. Id. (“Each agency uses its existing statutory authorities and regulations 
to ensure the safety of the biotechnology products for their intended 
applications. Underlying statutes define the boundaries of the scope of oversight 
afforded to each regulatory agency.”). 
 84. Id. at 28. 
 85. WHITE HOUSE, supra note 69, at 1. 
 86. Emily Marden & Deepti A. Kulkami, Regulatory Pathways Emerged for 
Gene-edited Products, LAW360 (Mar. 20, 2017), 
https://www.law360.com/articles/903715/regulatory-pathways-emerge-for-
gene-edited-products. 
 87. Id. 
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might not equip regulators with the best tools to regulate 
emerging biotechnological products effectively since gene-
editing technologies were not contemplated by Congress when 
these statutes were passed and amended.88 
F. CURRENT REGULATORY PATHWAYS OF GENETICALLY 
ENGINEERED ANIMALS WITH NON-CRISPR-LIKE TECHNOLOGIES 
Within the Coordinated Framework, genetically engineered 
animals using recombinant DNA or other similar technologies 
are regulated under different agencies with different statutory 
authorities according to their product area applications. Below 
is an outline of various existing regulatory pathways of 
genetically engineered animals.89 
i. New Animal Drugs  
In 2009, the FDA published a guidance regulating 
genetically engineered animals under the new animal drugs 
provisions under the FD & C Act by treating genetic material 
that is integrated into the animal as a new animal drug.90 The 
FDA followed the risk-based assessment laid out under the 
Coordinated Framework, considering the introduced DNA’s 
impact on animal health, effectiveness to the animal and, in the 
case of food-producing animals, whether food derived from the 
animal is safe for consumption.91 Under this guidance, the FDA 
                                                        
 88. See NAT’L ACAD. OF SCI., ENG’G, AND MED., supra note 68, at 173 
(acknowledging that “in some cases the jurisdiction of the agencies has the 
potential to leave gaps in regulatory oversight.”). 
 89. This Note also recognizes that the FDA regulates therapeutic and 
xenotransplantation products for human use derived from transgenic animals 
through guidance. Genetically engineered animals are also covered by 
applicable federal, state, local, and tribal laws pertaining to humane care, 
environmental safety, import and export, etc. This Note, however, does not go 
into detailed discussions of these regulations. 
 90. See 21 U.S.C. § 321(g)(1) (2018) (“The term ‘drug’ means: . . . (C) articles 
(other than food) intended to affect the structure or any function of the body of 
man or other animals.”). 21 U.S.C. § 321(v) (2018) (“The term ‘new animal drug’ 
means any drug intended for use for animals other than man . . . .”); Guidance 
for Industry on Regulation of Genetically Engineered Animals Containing 
Heritable Recombinant DNA Constructs, supra note 17 (maintaining that the 
rDNA construct in a genetically engineered animal that is intended to affect the 
structure or function of the body of the animal meets the FD & C Act’s drug 
definition). 
 91. See Guidance for Industry on Regulation of Genetically Engineered 
Animals Containing Heritable Recombinant DNA Constructs, supra note 17. 
WHITE HOUSE, supra note 69, at 19 (listing the seven categories that the FDA 
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has approved three animals,92 including the genetically 
engineered salmon for human consumption.93 
ii. New Drugs  
Under the FD & C Act, the FDA also has regulatory 
authority over new drugs that are developed through genetic 
engineering,94 which include drugs produced from genetically 
engineered animals.95 The FDA has developed regulations to 
evaluate whether the drug is safe and effective and whether the 
benefits outweigh the risks of the drug.96 
                                                        
applied in its review process: product definition, molecular characterization of 
the construct, molecular characterization of the GE animal lineage, phenotypic 
characterization of the GE animal, durability plan, environmental and food/feed 
safety, and claim validation); the FDA should also conduct an environmental 
assessment under the National Environmental Policy Act “with its approval of 
genetically engineered animals under its animal drug licensing authority and 
seek measures to ameliorate any anticipated adverse environmental effects.” 
NAT’L ACADS., ANIMAL BIOTECHNOLOGY: SCIENCE-BASED CONCERNS 164 
(2002). 
 92. See Sarah Polcz & Anna C.F. Lewis, A Menagerie of Moral Hazards: 
Regulating Genetically Modified Animals, 46 J. L. MED. & ETHICS 180, 183 
(2018) (including a goat that produces an anticlotting protein in its milk, a 
chicken whose eggs contain a drug for a specific cholesterol disease, and salmon 
that grows faster than normal). 
 93. See Ledford, supra note 60. Compare AquAdvantage Salmon Approval 
Letter and Appendix, U.S. FOOD & DRUG ADMIN. (updated Dec. 1, 2017), 
https://www.fda.gov/AnimalVeterinary/ucm466214.htm, and Freedom of 
Information Summary, U.S. FOOD & DRUG ADMIN., 
https://www.fda.gov/downloads/animalveterinary/developmentapprovalprocess
/geneticengineering/geneticallyengineeredanimals/ucm466215.pdf, with S. 230, 
112th Cong. (1st Sess. 2011) (proposing to amend the FD & C Act to prevent 
approval of the genetically engineered salmon), and H.R. 521, 112th Cong. (1st 
Sess. 2011) (preventing approval of the genetically engineered salmon). 
 94. See 21 U.S.C. § 321(p) (2018) (defining the term new drug as “any drug 
(except a new animal drug or an animal feed bearing or containing a new animal 
drug) the composition of which is such that such drug is not generally 
recognized . . . as safe and effective for use . . . .”). 
 95. See, e.g., Justin Caba, FDA Finally Approves the First Drug to Treat 
Rare Genetic Disease, Hereditary Angioedema, MED. DAILY (July 17, 2014), 
https://www.medicaldaily.com/fda-finally-approves-first-drug-treat-rare-
genetic-disease-hereditary-angioedema-293656 (reporting that the FDA 
approved a drug collected from the milk of lab-made rabbits to treat a genetic 
disease that causes body swelling). 
 96. See generally 21 U.S.C. § 355 (2018). 
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iii. Biologics 
 Under the Public Health Service Act, the FDA regulates 
biological products that are produced from genetically 
engineered animals.97 These biologics must be licensed by the 
FDA which considers whether they are safe and effective for 
their intended purpose.98 
iv. Animal Pests  
With the authority from the Animal Health Protection Act, 
the USDA has developed a framework to regulate genetically 
engineered animals by prohibiting or restricting imports or 
entry and interstate movement of them if they are animals that 
are considered livestock and that serve as animal pests 
transmitting diseases.99 The regulatory framework does not 
distinguish genetically engineered animals from non-genetically 
engineered animals; the USDA, when deciding whether to issue 
a permit for importing or transporting animal pests, considers 
the animal health risk and the mitigations that can be applied 
to reduce this risk.100 
v. Others  
The FDA and the USDA also share regulatory responsibility 
to ensure food from genetically engineered animals for human 
consumption is safe, wholesome, and correctly labeled.101 
Besides the FDA’s attempt to cover genetically engineered 
animals under the FD & C Act by categorizing inserted foreign 
                                                        
 97. See 42 U.S.C. § 262(i)(1) (2017) (“The term ‘biological product’ means a 
virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or 
derivative, allergenic product, protein (except any chemically synthesized 
polypeptide), or analogous product, or arsphenamine or derivative of 
arsphenamine (or any other trivalent organic arsenic compound), applicable to 
the prevention, treatment, or cure of a disease or condition of human beings.”). 
 98. See generally 42 U.S.C. §§ 262–263a-7 (1992). 
 99. See 7 U.S.C. § 8302(13) (2018) (“The term ‘pest’ means any of the 
following that can directly or indirectly injure, cause damage to, or cause 
disease in livestock: . . . (J) A vector. (K) Any organism similar to or allied with 
any of the organisms described in this paragraph.”); Framework for the 
Regulation of Genetically Engineered Animals and Insects Pursuant to the 
Animal Health Protection Act, 
https://www.aphis.usda.gov/animal_health/downloads/framework-ee-ahpa.pdf. 
 100. See Framework for the Regulation of Genetically Engineered Animals 
and Insects Pursuant to the Animal Health Protection Act, supra note 99. 
 101. See NAT’L ACADS., supra note 91, at 163 (including the FD & C Act, the 
Federal Meat Inspection Act, and the Poultry Products Inspection Act). 
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DNA sequences as a new animal drug,102 all the other 
regulations by various agencies have not stirred up controversies 
because they regulate genetically engineered animals in a way 
that are not distinguishable from non-genetically engineered 
animals. 
G. THE FDA’S UPDATED GUIDANCE OVER GENOME-EDITED 
ANIMALS WITH CRISPR-LIKE TECHNOLOGIES 
In January 2017, as part of the federal efforts to update the 
Coordinated Framework where the government was concerned 
that new biotechnological products would slip off the existing 
regulatory framework,103 the FDA published a draft updated 
guidance #187 which interprets the new animal drug provisions 
under the FD & C Act to cover products developed from CRISPR-
like precision gene-editing technologies.104 As explained in 
section F above, the previous guidance only addressed 
transgenic animals, but not genome-edited animals created with 
CRISPR-like technologies that result in “targeted DNA sequence 
changes including nucleotide insertions, substitutions, or 
deletions,” because the regulatory framework had not adapted 
to the development of new technologies.105 Thus, this new draft 
guidance is the FDA’s attempt to clarify that the altered genomic 
DNA in an animal is “an article that meets the definition of a 
new animal drug at each site in the genome where the alteration 
(insertion, substitution or deletion) occurs” and therefore shall 
                                                        
 102. See, e.g., GTC Biotherapeutics, Inc., Comment Letter on Food and Drug 
Administration Notice (Nov. 15, 2018), 
https://www.regulations.gov/document?D=FDA-2008-D-0394-0173 (arguing 
that “the [] Guidance stretches a proper interpretation of the law”); John J. 
Cohrssen & Henry I. Miller, Current FDA Approach to Genetically Engineered 
Animals Is Flawed, THE HILL (Nov. 6, 2017), 
https://thehill.com/opinion/healthcare/358893-current-fda-approach-to-
genetically-engineered-animals-is-flawed (categorizing the rDNA technology as 
one of the many animal breeding techniques and arguing that the animal drug 
provisions impose high evidentiary standard on developers). 
 103. See Waltz, supra note 79 and accompanying texts. 
 104. See Regulation of Intentionally Altered Genomic DNA in Animals Draft 
Guidance, supra note 18. See Nick Stockton, The FDA Wants to Regulate Edited 
Animal Genes as Drugs, WIRED (Jan. 24, 2017), 
https://www.wired.com/2017/01/fda-wants-regulate-edited-animal-genes-
drugs/. 
 105. Regulation of Intentionally Altered Genomic DNA in Animals Draft 
Guidance, supra note 18. 
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be covered by the FDA’s regulatory authority.106 Yet, this 
guidance has faced an unanticipated outcry from researchers, 
biotechnological companies, various environmental and industry 
groups, as well as other federal agencies.107 Part II will discuss 
the pitfalls of this guidance and propose alternative regulatory 
pathways for genome-edited animals if the FDA does not have 
the regulatory authority to do so. 
II. ANALYSIS 
Notably, current regulatory structures are not set up to 
regulate CRISPR-like technologies.108 This Part recognizes the 
FDA’s efforts to close the gaps under the current Coordinated 
Framework to regulate genome-edited animals with CRISPR-
like technologies through guidance #187 but argues that the 
FDA has exceeded its vested statutory authority under the FD 
& C Act which was passed in 1938. Furthermore, the FDA’s 
approach signals a departure from the product-based and risk-
based approach set in the Coordinated Framework. Rather, the 
FDA focuses on the process from which genome-edited animals 
are created. Moreover, instead of notice-and-comment 
rulemaking, the FDA has chosen to issue a guidance document 
that might not be adequate to address biotechnology products 
and the impacts of their application on the environment and 
human safety. Importantly, it is crucial to recognize that 
regulating more than necessary and implementing a stringent 
regulatory system will stifle innovation and shun scientists 
away while leaving a genome-edited product completely outside 
of regulatory oversight will be equally worrisome and stir up 
public concerns. Therefore, a balance must be struck between 
the competing concerns. 
                                                        
 106. Id. Cf. George Washington University Regulatory Studies Center, 
supra note 67 (noting that the guidance, however, excludes random 
mutagenesis followed by phenotypic selection). 
 107. See, e.g., Williams, supra note 74, at 454 (contending that researchers 
were hopeful that these gene-editing products would be regulated less 
stringently than animals that are genetically engineered by introducing foreign 
DNA). 
 108. See Greely, supra note 45 (noting that current statutes do not cover all 
that CRISPR can accomplish); Brooke Borel, The U.S. Regulations for 
Biotechnology Are Woefully Out of Date, SLATE (Apr. 21, 2017), 
http://www.slate.com/articles/technology/future_tense/2017/04/u_s_biotechnolo
gy_regulations_are_woefully_out_of_date.html. 
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A. THE FDA EXCEEDED ITS VESTED STATUTORY AUTHORITY TO 
INTERPRET ALTERED GENOMIC DNAS AS NEW ANIMAL DRUGS. 
Congress expressly delegated the authority of regulating 
new animal drugs to the FDA under the FD & C Act which sets 
the boundaries of the FDA’s scope of regulation.109 The FDA has 
exceeded its vested authority by interpreting altered genomic 
DNAs as new animal drugs.110 Under the FD & C Act, a new 
animal drug is defined as “any drug intended for use for animals 
other than man . . . . .”111 To qualify as a new animal drug, the 
application must be a drug first which means an “article[] 
intended to affect the structure or any function of the body of 
man or other animals.”112 The FDA characterizes genome-edited 
animals as equivalent to transgenic animals and thus treats 
altered genomic DNA as the regulated article.113 However, many 
industry groups or nonprofits disagree with the FDA’s 
characterization and argue that the FDA’s attempt to assert 
jurisdiction over the production and commercialization of 
genome-edited animals is ultra vires because altered genomic 
DNAs could not or would not be drugs.114 
When the FDA issued the 2009 guidance to exercise 
oversight of the recombinant DNA construct to an animal as new 
animal drugs based on which it approved several transgenic 
animals, it was already testing the limit of the scope of authority 
vested by Congress under the FD&C Act. In the FDA’s most 
recent guidance, however, it has moved past the tipping point 
because under certain circumstances CRISPR-like technologies 
do not involve insertion of foreign DNAs into the genome of a 
targeted animal. 
The FDA’s interpretation of a drug is erroneous. Under the 
FD&C Act, a drug must be an article “intended to affect the 
structure or any function of the body of man or other animals.”115 
                                                        
 109. See generally 21 U.S.C. § 360b (2018). 
 110. See Guidance for Industry on Regulation of Genetically Engineered 
Animals Containing Heritable Recombinant DNA Constructs, supra note 17. 
 111. 21 U.S.C. § 321(v) (2018). 
 112. 21 U.S.C. § 321(g)(1)(C) (2018). 
 113. See Guidance for Industry on Regulation of Genetically Engineered 
Animals Containing Heritable Recombinant DNA Constructs, supra note 17. 
 114. See, e.g., Ctr. for Food Safety, supra note 21; cf. Consumers Union, 
supra note 19. 
 115. 21 U.S.C. § 321(g)(1)(C) (2018); see also 21 U.S.C. § 321(g)(1), supra 
note 90 and accompanying texts. 
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Unquestionably, the altered genomic DNA affects the structure 
or function of the animal to obtain desirable traits; for example, 
the altered genomic DNA in the cattle transforms it into a 
hornless one.116 Nevertheless, the altered genomic DNA is not 
an article. The FD&C Act does not define article and the FDA 
has pointed out that the term has a “broad meaning” throughout 
the FD & C Act.117 The dictionary definition of “article” is “a 
thing or person of a . . . distinctive kind or class.”118 Distinctive 
means “separate or different.”119 Thus, an article must be 
separate and different from the recipient animal and therefore 
is “a necessary addition to induce a change to the structure or 
function of man or animal.”120 
Under certain circumstances, altered genomic DNAs using 
CRISPR-like technologies are not separate articles that are 
introduced into the recipient animal, but rather, products 
resulted from the cutting of Cas9 enzyme in vivo.121 When using 
CRISPR-Cas9 to delete genetic material from the target cell, 
scientists introduce nothing new into the genome and the altered 
genomic DNA does not contain any foreign article that modifies 
the structure or function of the animal.122 The FDA must 
distinguish this gene-editing process from a transgenesis 
process where a recombinant DNA construct is created 
externally outside an animal and then inserted into the animal’s 
genome. With genome-edited animals, the targeted DNA 
sequences are part of the animal’s genome, not a foreign 
addition, and the gene-editing process occurs completely in vivo, 
not ex vivo.123 Therefore, the altered genomic DNA does not fit 
the definition of a drug under the FD & C Act because of the 
absence of an article as “a necessary addition” to the animal.124 
                                                        
 116. See supra Section I.B. 
 117. See 21 U.S.C. § 321 (2018); see also Pharmanex v. Shalala, 221 F.3d 
1151, 1155 (10th Cir. 2000). 
 118. Article, MERRIAM-WEBSTER DICTIONARY (2019). 
 119. Distinctive, MERRIAM-WEBSTER DICTIONARY (2019). 
 120. Nat’l Milk Producers Fed’n, Comment Letter on The Food and Drug 
Administration’s Draft Guidance for Industry #187 “Regulation of Intentionally 
Altered Genomic DNA in Animals” (June 19, 2017), 
https://www.regulations.gov/document?D=FDA-2008-D-0394-0413. 
 121. See supra section I.A. 
 122. See Nat’lMilk Producers Fed’n, supra note 121. 
 123. See id. 
 124. The conclusion of this section has limited implication on gene therapy 
using CRISPR-like technologies. Currently, the FDA regulates gene and cell 
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B. THE FDA’S GUIDANCE DEVIATES FROM THE CONVENTIONAL 
PRODUCT-BASED REGULATORY SCHEME SET FORTH IN THE 
COORDINATED FRAMEWORK. 
Other than the legal flaws identified above, the FDA’s 
guidance has not followed the policy set forth under the 
Coordinated Framework. The guidance deviates from the 
traditional product-based approach and focuses on the process 
that the animals are created by using CRISPR-like technologies 
instead.125 It assumes that all gene-editing techniques are 
dangerous and “deemed unsafe” by construing altered genomic 
DNAs as new animal drugs.126 
New gene-editing technologies like CRISPR-Cas9 underpin 
the inherent flaws of a process-based approach. First, animals 
created from gene-editing technologies impose less risk than 
those created from recombinant DNA technologies.127 Currently, 
there is no scientifically objective method to distinguish animals 
created from conventional breeding methods from animals 
developed through use of gene-editing methods,128 and 
sometimes conventionally bred animals pose more risk than 
                                                        
therapy products under, among others, the Investigational New Drug 
Application. 21 C.F.R. § 312. When a cell is modified ex vivo for subsequent 
administration to humans, the cell can be construed as a drug under the FD & 
C Act. However, when the cell is altered in vivo using CRISPR-like technologies, 
no foreign article is inserted into the cell which cannot be construed as a drug 
itself. Regardless, the FDA has created expedited programs for regenerative 
medicine therapies that include human gene therapies, regardless how a cell is 
modified. See generally Expedited Programs for Regenerative Medicine 
Therapies for Serious Conditions: Draft Guidance for Industry, 82 FED. REG. 
4825 (Feb. 19, 2019). 
 125. See supra note 73 and accompanying texts. Cf. James D. Murray & 
Elizabeth A. Maga, Regulatory Dysfunction Inhibits the Development and 
Application of Transgenic Livestock for Use in Agriculture, in ANIMAL 
BIOTECHNOLOGY 2: REPRODUCTIVE BIOTECHNOLOGIES 149, 157 (Heiner 
Niemann & Christine Wrenzycki eds., 2018) (finding that to date, worldwide 
governments have for the most part chosen to regulate the process of making a 
genetically engineered animal instead of the resulting product). 
 126. Regulation of Intentionally Altered Genomic DNA in Animals Draft 
Guidance, supra note 18. 
 127. See Section I.B. 
 128. The George Washington University Regulatory Studies Center, supra 
note 67, at 6; Jonas J. Monast, Editing Nature: Reconceptualizing Biotechnology 
Governance, 59 B. C. L. REV. 2377, 2399 (2018) (arguing that if CRISPR is 
analogous to selective breeding or natural selection, it follows that genome-
edited organisms are no less natural than their counterparts that could foster 
similar genetic changes through conventional reproduction). 
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genome-edited animals.129 Thus, under a process-based 
approach, genome-edited animals are subject to a similar or 
higher level of regulation than transgenic and conventionally 
bred animals even though genome-edited animals entail less 
risk of unintended changes to the genome.130 An assumption of 
risk based solely on the use of a certain technique runs against 
the Coordinated Framework and can warrant regulatory 
oversight by the FDA. 
Second, a process-based approach would stunt scientific 
development in gene-editing or other biotechnologies.131 If pre-
market oversight is imposed on all genome-edited animals using 
CRISPR-like techniques, only big corporations would be able to 
afford expensive and time-consuming health and environmental 
assessments while small companies would be unable to finance 
these costly safety assessments.132 One might argue that only 
big corporations should be allowed to carry out biotechnology 
                                                        
 129. See George Washington University Regulatory Studies Center, supra 
note 67, at 6 (finding that random mutagenesis followed by phenotypic selection 
would result in more genome alterations). 
 130. See Alison Peck, Re-Framing Biotechnology Regulation, 72 FOOD & 
DRUG L. J. 314, 331–33 (2017) (finding that under a process-based approach, 
conventional breeding technologies would also fall under the scope of 
regulation); Pak, supra note 23 (discussing whether CRISPR-Cas9 is genetic 
engineering or a form of mutagenesis which is not subject to U.S. regulation); 
Kathleen M. Vogel, Crispr Goes Global: A Snapshot of Rules, Policies, and 
Attitudes, THE BULLETIN (June 5, 2018), https://thebulletin.org/2018/06/crispr-
goes-global-a-snapshot-of-rules-policies-and-attitudes/ (finding that the EU 
court exempted crops created by gene-editing technologies from regulations 
because the result is nature-identical); see also Gregory Conko et al., A Risk-
based Approach to the Regulation of Genetically Engineered Organisms, 34 
NATURE BIOTECHNOLOGY 493 (2016) (finding that most regulatory regimes 
around the world do not follow the risk-based approach and that the degree of 
regulatory scrutiny in most cases is inversely proportional to the risk). 
 131. See Tomlinson, supra note 8, at 461 (quoting that the irony of subjecting 
groundbreaking scientific discoveries to an archaic regulatory scheme is 
causing many researchers to lose faith in the system); Marden & Kulkami, 
supra note 86 (exploring the impracticability of proposed regulatory changes 
that slow down development). 
 132. Rubin & Sax, supra note 72, at 596–97 (“Depending on how many 
agencies a firm may need to petition or voluntarily consult, the process 
currently requires ten years to bring a new GM product to market.”); Jack 
Karsten & Darrell M. West, New Biotech Regulations Require Balance of Safety 
and 
Innovation, BROOKINGS (Mar. 3, 2017), 
https://www.brookings.edu/blog/techtank/2017/03/03/new-biotech-regulations-
require-balance-of-safety-and-innovation/ (discussing concern for proposed 
regulations that could limit competition and innovation). 
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research because of their efficiency, economies of scale, and high 
standards of quality, but these advantages of big corporations 
seem ironic when CRISPR-like technologies democratize 
scientific applications and make gene-editing more accessible 
and economical.133 The stringent process-based approach will 
likely push innovations to jurisdictions that provide a regulatory 
environment more hospitable to entrepreneurial activities and 
cause the U.S. to lose its competitive advantage in biotechnology 
fields.134 
Third, a process-based regulatory approach would almost 
inevitably fall behind time and future development of 
biotechnology products.135 Soon, there will be new technologies 
beyond CRISPR-Cas9 such as genomically recoded organisms 
created via synthetic DNA.136 Agencies simply do not have the 
resources to develop new regulations in reaction to every new 
technology,137 and a constantly changing regulatory landscape 
creates regulatory uncertainties that might stifle innovation.138 
In contrast, a product-based approach “specifies required 
outcomes or objectives rather than defining the way in which 
                                                        
 133. See supra section I.B. 
 134. Thierer, supra note 22 (“If policymakers erect more obstacles to 
innovation, it will encourage entrepreneurs to look elsewhere when considering 
the most hospitable place to undertake their innovative activities.”); see Kevin 
Bryant, Ph.D., Top 9 CRISPR Startup Companies Changing the Future of 
Biotech and Medicine, SYNTHEGO, https://www.synthego.com/blog/crispr-
startup-companies (last updated Jan. 3, 2019) (providing a list of startups 
applying CRISPR to various fields). 
 135. See NAT’L ACAD. OF SCI., ENG’G, AND MED., supra note 68, at 174 (“The 
profusion of future biotechnology products anticipated in coming years will 
challenge the federal agencies’ ability to handle significant increases in the rate 
of biotechnology product innovation, the number of biotechnology products, the 
complexity of interactions, and the diversity of actors (and their experience with 
the regulatory process).”). 
 136. Id. at 172. 
 137. For example, the FDA had to create new guidance documents from 2009 
to 2017 in reaction to the emerging technologies like CRISPR-Cas9. William D. 
Eggers, Mike Turley & Pankaj Kishnani, The Future of Regulation: Principles 
for Regulating Emerging Technologies, DELOITTE INSIGHTS (June 19, 2018), 
https://www2.deloitte.com/insights/us/en/industry/public-sector/future-of-
regulation/regulating-emerging-technology.html (“The policy cycle often takes 
anything from five to 20 years whereas a unicorn startup can develop into a 
company with global reach in a matter of months.”). 
 138. See also Ann Bruce, Novel GM Animal Technologies and Their 
Governance, 22 TRANSGENIC RES. 681, 688 (2013) (arguing that regulatory 
uncertainty would also make it difficult for developers to assess the relative 
commercial advantage of the new technology and limit market innovation). 
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they must be achieved.”139 This approach is better at adapting to 
scaling modern innovations because the outcomes set by the 
regulators are unaffected by the development of new 
technologies. 
Thus, when carrying out a benefit-risk assessment,140 the 
FDA should have considered the risks of the product, the 
genome-edited animal, not the risks of the process, CRISPR-
Cas9. It should have considered the effects of modified genetic 
material on the animal and whether food derived from the 
animal is safe for human consumption.141 For the forgoing 
reasons, the FDA should ground its regulatory approach in the 
product-based approach identified in the Coordinated 
Framework. 
C. WHEN FACING A SIMILAR SITUATION, THE USDA ADHERED TO 
THE PRODUCT-BASED APPROACH AND EXCLUDED GENOME-
EDITED CROPS WITH CRISPR-LIKE TECHNOLOGIES FROM ITS 
JURISDICTION. 
This Note recognizes that existing statutes and the current 
framework were not conceived to cover biotechnologies like 
CRISPR-Cas9. Nevertheless, it is not impossible to work with 
existing statutes while conforming to the Coordinated 
Framework. In 2016, the USDA had to determine whether it has 
the jurisdiction to regulate a type of CRISPR-edited anti-
browning mushroom.142 Under the USDA’s regulation, a 
genetically engineered organism is deemed a regulated article “if 
it has been genetically engineered using a donor 
organism . . . that . . . meets the definition of a plant 
pest . . . .”143 Unlike the FDA, the USDA determined that the 
genome-edited mushroom was beyond its regulatory authority 
because the “CRISPR/Cas9-edited white button 
                                                        
 139. Eggers, Turley & Kishnani, supra note 138. 
 140. See 21 U.S.C. § 355(d) (2018) (requiring a risk-benefit assessment 
framework). 
 141. See Nat’l Assn. of State Dep’t of Agric., supra note 21 (arguing for these 
considerations). 
 142. See U.S. Dep’t of Agric., Re: Request for Confirmation that Transgene-
free, CRISPR-edited Mushroom Is Not a Regulated Article (Apr. 13, 2016) 
[hereinafter USDA Confirmation Request] 
https://www.aphis.usda.gov/biotechnology/downloads/reg_loi/15-321-
01_air_response_signed.pdf (assessing the potential regulation of the 
mushroom in question). 
 143. 7 C.F.R. § 340.1 (2019). 
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mushrooms . . . do not contain any introduced genetic 
material,”144 and therefore, is not a regulated article. 
Additionally, the USDA announced that it would not 
regulate crops that “could otherwise have been developed 
through traditional breeding techniques as long as they are not 
plant pests or developed using plant pests.”145 Genome-edited 
plants with CRISPR-like technologies could also be obtained 
through traditional breeding techniques as they do not contain 
artificially inserted genes from other species.146 Therefore, they 
will not be overseen by the USDA. Compared to the FDA’s 
approach, the USDA’s approach towards genome-edited plants 
is much more nuanced, distinguishing genome-edited plants 
from genetically engineered plants by recombinant DNA 
techniques and adhering to the product-based approach outlined 
under the Coordinated Framework. The FDA could have 
adopted a similar approach towards genome-edited animals to 
encourage more beneficial innovations. 
D. THE FDA SHOULD HAVE PROMULGATED RULES VIA NOTICE-
AND-COMMENT PROCEDURE. 
Lastly, the FDA could have promulgated a rule via the 
notice-and-comment process that would determine the 
circumstances under which genome-edited animals could be 
brought into the market, but it chose to issue a non-binding 
guidance document instead. The FDA defines guidance 
documents in its Good Guidance Practices (GGPs) as documents 
that “describe the agency’s interpretation of or policy on a 
regulatory issue” and establish no “legally enforceable rights or 
responsibilities.”147 Yet, when the FDA interprets the new 
animal drug provisions under the FD&C Act to cover altered 
genomic DNAs, instead of making an interpretive rule, it is 
                                                        
 144. USDA Confirmation Request, supra note 143; see also Irus Braverman, 
Editing the Environment: Emerging Issues in Genetics and the Law, in GENE 
EDITING, LAW, AND THE ENVIRONMENT: LIFE BEYOND THE HUMAN 1, 7 (Irus 
Braverman ed., 2018) (discussing the USDA’s decision regarding the 
mushroom). 
 145. Press Release, U.S. Dep’t of Agric., Secretary Perdue Issues USDA 
Statement on Plant Breeding Innovation (Mar. 28, 2018), 
https://www.usda.gov/media/press-releases/2018/03/28/secretary-perdue-
issues-usda-statement-plant-breeding-innovation (“With this approach, USDA 
seeks to allow innovation when there is no risk present.”). 
 146. See supra section I.B. 
 147. 21 C.F.R. § 10.115 (2018). 
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actually making a legislative rule which imposes “a definitive 
obligation on a group of private persons.”148 Though the GGPs 
pronounces that a guidance document is not binding and affected 
parties may choose alternative approaches other than the one 
set forth in a guidance document,149 the regulated parties would 
not “feel comfortable using anything other than the suggested 
form.”150 
Moreover, guidance documents afford little procedural 
safeguard to the public. The notice-and-comment process 
provides interested individuals with a meaningful opportunity 
to comment on the proposed rule through the submission of 
written “data, views, or arguments,”151 of which significant 
comments must be incorporated into the final rule.152 Affected 
individuals may challenge the rulemaking process on an 
arbitrary and capricious standard if the agency fails to consider 
public comments.153 Guidance documents, however, are exempt 
from this requirement. Section 553 of the Administrative 
Procedure Act (APA) provides that “interpretative rules, general 
statements of policy, or rules of agency organization” are 
excluded from the notice-and-comment requirements, and 
administrative guidance falls under the exception of 
interpretative rules.154 Instead of addressing all significant 
comments in the final rule, the FDA only needs to incorporate 
comments if it deems appropriate.155 By resorting to issuing an 
administrative guidance, the FDA attempted to circumvent the 
increasing scrutiny the courts have devoted to notice-and-
comment rulemaking.156 
                                                        
 148. Rubin & Sax, supra note 72, at 571. 
 149. See 21 C.F.R. § 10.115 (2018). 
 150. See Rubin & Sax, supra note 72, at 571–72 (“In legal doctrine or a law-
school classroom, there may be a great difference between disobeying and 
annoying a government agency, but in the real, regulated world, that difference 
is not as evident.”). 
 151. 5 U.S.C. § 553(c) (2018). 
 152. See Perez v. Mortg. Bankers Ass’n, 135 S. Ct. 1199, 1203 (2015) (“An 
agency must consider and respond to significant comments received during the 
period for public comment.”). 
 153. See 5 U.S.C. § 706(2)(A) (2018) (invoking the arbitrary and capricious 
standard). 
 154. 5 U.S.C. § 553(b)(3)(A) (2018). 
 155. See 21 C.F.R. § 10.115 (2018). 
 156. Rubin & Sax, supra note 72, at 540–42, 566 (criticizing guidance as an 
improper attempt of rulemaking and one of the most controversial techniques 
in administrative law). 
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Notably, one might argue that by issuing a guidance 
document which is a soft law mechanism, agencies can now 
adapt quickly to changes in technology and address issues as 
they arise without stifling innovation.157 However, when 
regulated products might potentially pose unknown risks to the 
environment and human health, the regulation should, at least, 
provide a basis for a legal challenge and thus allow for judicial 
review.158 The public needs an avenue to understand genome-
edited products and thereby “reduc[e] irrational fears about 
[their] safety,” and small firms need an avenue to promote the 
benefits they could offer to the public and the market, “or at least 
compel the [a]gency to defend the burdens it imposes on these 
firms.”159 Thus, a guidance document which does not confer the 
public with a sufficient participatory mechanism is not the best 
tool to deal with genome-edited products and the FDA should 
have issued a rule through the informal rulemaking process 
under the APA. 
The FDA’s guidance #187 faces so many legal, procedural, 
and policy challenges that the agency must come up with a new 
regulatory approach towards genome-edited animals with 
CRISPR-like techniques. If the FDA were to find that it lacks 
any authority to extend its jurisdiction over genome-edited 
animals, other agencies might be able to fill in this gap. 
III. POLICY CONSIDERATIONS MOVING FORWARD 
The analysis above has identified a few gaps within the 
current regulatory structures, which were not created to 
regulate genome-edited animals with emerging biotechnologies. 
Therefore, with these pitfalls of the FDA’s draft guidance, this 
Part proposes several alternative pathways to regulate genome-
edited animals with CRISPR-like technologies. Additionally, 
under the current Coordinated Framework, agencies follow a 
product- and risk-based approach to regulate genome-edited 
                                                        
 157. See William McGeveran, Friending the Privacy Regulators, 58 ARIZ. L. 
R. 959, 987 (2016) (explaining how flexible regulation can help regulators 
remain responsive to rapid technological change). 
 158. Cf. Rubin & Sax, supra note 72, at 587 (highlighting the weakness in 
the Coordinated Framework used to regulate genetically modified food because, 
as an administrative guidance, and thus a planning document, it provided no 
basis for a legal challenge or judicial review). 
 159. Id. at 599. 
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animals.160 However, a traditional risk-based approach faces 
limitations in the context of new biotechnologies such as 
CRISPR-Cas9 when the risks associated are uncertain and 
ambiguous. Thus, there is an urgent need for the White House 
to creates a framework with a single point of entry to regulate 
genome-edited products, and update the Coordinate Framework 
to incorporate the Responsible Research and Innovation (RRI) 
principles to balance precaution and innovation, process and 
product, as well as interests of developers and the public. 
A. REGULATORY GAP AND ALTERNATIVE REGULATORY 
PATHWAYS FOR GENOME-EDITED ANIMALS WITH CRISPR-LIKE 
TECHNOLOGIES UNDER EXISTING STATUTES 
Although the FDA’s updated guidance has many 
controversial aspects of regulating genome-edited animals, it 
indicates the agency’s attempt to fill in the gap of agency 
jurisdiction under the Coordinated Framework. Were the FDA 
to find that it lacks the jurisdiction to cover genome-edited 
animals under existing statutes, letting them fall completely 
outside of oversight, like how the anti-browning mushroom fell 
outside of the USDA’s jurisdiction, it might not be an assuring 
idea for the public at large.161 
The FDA no longer has to be the lead agency exercising 
oversight of animals for human use after the 2017 update to the 
Coordinate Framework which encouraged agencies to coordinate 
amongst each other.162 Therefore, federal agencies might explore 
alternative pathways to exercise oversight of genome-edited 
animals with CRISPR-like technologies.163 One possible solution 
                                                        
 160. See WHITE HOUSE, supra note 69, at 8 (“Exercise of agency oversight 
within the scope afforded by statutes should be commensurate with the risk 
posed by the introduction of the biotechnology product and should not turn on 
the fact that it was created or has been altered by a particular process or 
technique.”). 
 161. See Mark Shwartz, Target, Delete, Repair, STAN. MED., 
https://stanmed.stanford.edu/2018winter/CRISPR-for-gene-editing-is-
revolutionary-but-it-comes-with-risks.html (last visited Mar. 26, 2019) (“When 
it comes to experiments on animals, . . . two things worry me . . . . One is the 
intentional misuse of CRISPR. The other is that people with good intentions 
will inadvertently cause harm.”) (citing Stanford bioethicist Hank Greely, JD). 
 162. See WHITE HOUSE, supra note 69, at 29. 
 163. The FDA could still exercise oversight of genome-edited animals if they 
are used to create new human drugs and biological products; the USDA could 
continue regulating genome-edited animals as animal pests that transmit 
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for the agencies, a solution that has not been explored at all, is 
to regulate the construct inserted into the targeted animal—the 
guide RNA and the Cas9 protein—instead of the altered genomic 
DNA. 
i. New Animal Drug under the FD&C Act 
Although the altered genomic DNA is not a drug, the FDA 
might, one day, regulate the guide-RNA/Cas9 construct inserted 
into the targeted animal as a new animal drug.164 The key 
question to determine is whether this construct constitutes a 
drug or medical device. Under the FD&C Act, a medical device 
is an article that is “intended to affect the structure or any 
function of the body of man or other animals” and “does not 
achieve its primary intended purposes through chemical 
action.”165 When the construct is inserted into the targeted cell, 
Cas9 binds specifically to the targeted DNA and cleaves the two 
DNA strands to get rid of particular genetic material.166 It is 
generally acknowledged among scientists that when Cas9 
cleaves the DNA strands, it is catalyzing the splitting of the 
chemical bonds in the strands.167 If the DNA cleavage is 
characterized as a chemical action, then the construct will likely 
be a new animal drug; otherwise, the construct will likely be a 
medical device. 
The interpretation of the term “chemical action” is a 
nuanced one that the FDA and the scientific community 
constantly grapple with.168 The FDA clarified in the guidance 
that “a product that exhibits . . . intermolecular forces does not 
                                                        
diseases. For regulatory purposes, genome-edited animals are not 
distinguishable from other animals. See supra section I.F. 
 164. The FDA is charged with protecting the public health by ensuring that 
animal drugs are safe and effective. 21 U.S.C. § 393(b)(2)(B) (2018). 
 165. 21 U.S.C. § 321(h)(3) (2018). 
 166. See GALLO ET AL., supra note 10, at 2–3 (explaining how the CRISPR-
Cas9 system functions). 
 167. See, e.g., Cong Huai et al., Structural Insights into DNA Cleavage 
Activation of CRISPR-Cas9 System, NATURE COMM. 2 (Nov. 9, 2017), 
https://www.nature.com/articles/s41467-017-01496-2 (“[T]hen, the two nuclease 
domains (HNH and RuvC) catalyze the splitting of the scissile [covalent 
chemical] bonds in two DNA strands, respectively.”). 
 168. See Classification of Products as Drugs and Devices and Additional 
Product Classification Issues, 82 FED. REG. 44802, 44803 (Sept. 26, 2017) 
(explaining how following public comments the FDA revised the guidance to 
more clearly explain the agency’s thinking regarding the interpretation of 
“chemical action.”). 
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exhibit ‘chemical action’ under section 210(h) unless the 
product . . . mediates a bodily response at the cellular or 
molecular level . . . .”169 The guidance also illustrates that a 
catalyst interacts with the body through intermolecular forces 
and “mediates a bodily response at the cellular or molecular level 
by catalyzing a number of enzymatic reactions of the 
body . . . .”170 Similar to the catalyst example, when Cas9 binds 
to the targeted DNA and cleaves the strands, it interacts with 
the strands through intermolecular forces and triggers the cell 
to repair the damage by such cleavage.171 Therefore, it is likely 
that the DNA cleavage exhibits chemical action and thus, the 
guide-RNA/Cas9 construct is not a medical device, but a drug 
under the FD & C Act. 
ii. Veterinary Biologic under the Virus-Serum-Toxin Act 
(VSTA) 
Alternatively, the USDA might be able to construe the 
guide-RNA/Cas9 construct as a veterinary biologic and thus 
regulate it under the VSTA.172 Veterinary biologics are “products 
derived from living organisms and biological processes” that are 
“used to prevent, diagnose, or treat animal diseases.”173 The 
USDA must approve a veterinary biologic to be “pure, safe, 
potent, and efficacious” before it is introduced into the market.174 
Currently, scientists have succeeded in disrupting the prion 
gene that can cause the mad cow disease with CRISPR-Cas9 to 
                                                        
 169. FOOD & DRUG ADMIN., GUIDANCE FOR THE INDUSTRY AND FDA STAFF: 
INTERPRETATION OF THE TERM ‘CHEMICAL ACTION’ IN THE DEFINITION OF 
DEVICE UNDER SECTION 201(H) OF THE FEDERAL FOOD, DRUG, AND COSMETIC 
ACT 3 (2017), available at 
https://www.pharmamedtechbi.com/~/media/Supporting%20Documents/The%
20Gray%20Sheet/38/40/chemical_action_guidance.pdf (distributing a draft 
guidance for comment purposes only). 
 170. Id. 
 171. See Univ. of Cal. Berkeley, supra note 39. 
 172. See generally 21 U.S.C. §§ 151–159 (2018) (conferring authority for the 
Secretary of Agriculture to regulate “any virus, serum, toxin, or analogous 
product for use in the treatment of domestic animals.”). 
 173. U.S. DEP’T AGRIC., PROGRAM AID NO. 1713, VETERINARY BIOLOGICS: 
USE AND REGULATION 1 (2013). The statute does not define the term “veterinary 
biologic.” See 21 C.F.R. § 510.3 (listing definitions). 
 174. Common Questions About Veterinary Biologics, U.S. DEP’T OF AGRIC., 
https://www.aphis.usda.gov/aphis/ourfocus/animalhealth/veterinary-
biologics/ct_vb_pel_faqs (last modified July 17, 2015). 
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prevent cattle from contracting the disease.175 In this case, the 
guide-RNA/Cas9 construct can be construed as a veterinary 
biologic that prevents animal diseases in cattle by knocking out 
the responsible gene, since the USDA already licensed the first 
veterinary RNA vaccine in 2012.176 As such, the USDA might be 
able to regulate the guide-RNA/Cas9 construct as a veterinary 
biologic. 
iii. Pesticide Under the Federal Insecticide, Fungicide, and 
Rodenticide Act (FIFRA) 
Lastly, the EPA might be able to construe the guide-
RNA/Cas9 construct as a pesticide and thus regulate it under 
the FIFRA.177 Pesticide means any substance “intended for 
preventing, destroying, repelling, or mitigating any pest.”178 In 
the United States, genetically engineered insects have already 
been released into the environment—Oxitec mosquitoes that 
combat Zika—and have been regulated as a pesticide by the EPA 
because they are intended to reduce the population of 
mosquitoes in future generations and bring the species to its 
extinction.179 Recently, scientists have succeeded in using 
CRISPR-Cas9 to wipe out a type of mosquito “in as few as seven 
                                                        
 175. See THE NETH. COMM’N ON GENETIC MODIFICATION, CRISPR & 
ANIMALS: IMPLICATIONS OF GENOME EDITING FOR POLICY AND SOCIETY 34 
(2018); see also Helen Briggs, ‘Tuberculosis-resistant’ Cattle Developed in China, 
BBC (Feb. 1, 2017), https://www.bbc.com/news/science-environment-38810073 
(reporting tuberculosis-resistant cattle has been created using the CRISPR-
Cas9 system). 
 176. U.S. DEP’T OF AGRIC., supra note 173, at 9; see also New Swine Flu 
Vaccine Licensed, NAT’L HOG FARMER (Oct. 8, 2012), 
https://www.nationalhogfarmer.com/health/new-swine-flu-vaccine-licensed 
(reporting that the USDA approved a swine influenza virus H3N2 vaccine that 
utilizes RNA Particle Technology). 
 177. The EPA is charged with protecting human health and the environment 
by ensuring registered pesticide products result in no unreasonable adverse 
effects to man or the environment. 7 U.S.C. § 136a(c)(5) (2018). 
 178. 7 U.S.C.§ 136(u) (2018). 
 179. See U.S. FOOD & DRUG ADMIN., CLARIFICATION OF FDA AND EPA 
JURISDICTION OVER MOSQUITO-RELATED PRODUCTS: GUIDANCE FOR INDUSTRY 
6 (2017) (clarifying the regulatory role the EPA shares in gene edited 
mosquitos); Andrew Hammond, Here’s the Plan to End Malaria with CRISPR-
edited Mosquitoes, WIRED (Sept. 24, 2018), https://www.wired.com/story/heres-
the-plan-to-end-malaria-with-crispr-edited-mosquitoes/ (explaining how 
genetically modified sterile mosquitos were released into the wild to combat 
Zika in America). 
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generations.”180 In this case, the guide-RNA/Cas9 construct 
inserted into the mosquito genome, together with the resulted 
mosquito, functions as a pesticide that annihilates the mosquito 
population, making it subject to the EPA’s jurisdiction.181 Future 
pesticide-like genome-edited animals might also be subject to 
this regulatory pathway instead of being regulated by the FDA. 
Although these agencies might be vested with the statutory 
authority to exercise oversight of the guide-RNA/Cas9 construct, 
it might not be a sound policy for them to do so because 
regulating the construct in this way would focus purely on the 
process, running counter to the product-based approached laid 
out under the Coordinated Framework.182 Additionally, with the 
constant change in technologies, regulations cannot be grounded 
in a particular process but must stay flexible to remain relevant 
and effective.183 As such, the White House must set up a new 
framework to facilitate the agencies to determine the fine 
balance between encouraging innovation and rendering 
oversight of new technologies. 
B. THE WHITE HOUSE SHALL UPDATE THE COORDINATED 
FRAMEWORK WITH THE RRI PRINCIPLES THAT BALANCES 
PRECAUTION AND INNOVATION POTENTIAL OF GENOME-EDITED 
PRODUCTS 
i. Limitations of a Risk-Based Approach towards Genome-
Edited Products 
The Coordinated Framework has adopted a risk-based 
approach towards biotechnological products.184 As explained in 
the section above, a risk-based approach assesses risks based on 
characteristics of the organism, the target environment, and the 
                                                        
 180. Hammond, supra note 179. 
 181. See U.S. FOOD & DRUG ADMIN., supra note 179. 
 182. See discussions supra section II.A.ii. 
 183. See NAT’L ACAD. OF SCI., ENG’G, AND MED., supra note 68, at 93–99 
(“[A]lthough the products of future biotechnology are often likely to be within 
the jurisdiction of existing regulators, they may struggle to regulate these 
products effectively and to respond nimbly to the products that will be coming.”); 
Meagan Davis, The Proper Regulation and the Use of CRISPR/Cas9 in the 21st 
Century 14 (Apr. 2018) (unpublished student essay) (on file with the College of 
Saint Benedict/Saint John’s University) (“With the constant change of 
technology, regulations need flexibility and stability to stay relevant and 
effective”). 
 184. See Meghani, supra note 73 and accompanying texts. 
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type of application.185 Currently, the quantitative risk 
assessment is widely used for new biotechnological products, 
which means that the risk of the new organism on the ecologic 
environment and human health is quantified by measurable, 
objective data.186 
However, a risk-based assessment works best only when the 
risks are “clearly defined and quantifiable.”187 Risks of genome-
edited animals with emerging biotechnologies like CRISPR-
Cas9 are uncertain, ambiguous, and unfamiliar because of their 
“inherent fluid boundaries, possible fields of application, and the 
unknown and extremely dynamic future developments.”188 
Currently, there is no sufficient baseline of information to 
accurately assess the risks of products created with new 
technologies.189 Thus, a risk-based approach is handicapped 
when the risks of genome-edited products cannot be quantified 
and evaluated against their benefits. 
ii. Moving toward RRI to Address Risks While Fostering 
Public-Welfare-Oriented Responsible Innovation 
Given the unique nature of CRISPR-like technologies and 
the likelihood of having future biotechnologies that no one could 
have foreseen, U.S. agencies should move towards an approach 
that finds the right balance between precaution and 
innovation.190 On the one hand, regulators should be wary of the 
unknown risks associated with genome-edited products on the 
environment, human health, and safety. On the other hand, 
regulatory agencies cannot inhibit innovation.191 Future 
regulation will need to balance the dynamic relationships of “the 
nature of the innovative products developed, their areas of 
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application, and the time-scales for their development.”192 When 
in doubt, responsible governance demands the agencies “give 
precedence to the protection of human dignity, human health or 
the environment, rather than to organizational or economic 
interests.”193 
With these principles in mind, the White House could 
update the Coordinated Framework with the RRI principles and 
move towards a participatory approach that allows the agencies 
to work with all societal actors during the innovation process 
and to bring out new technologies that are reconciled with 
societal values, needs, and expectations.194 Philosopher and 
Scientist René von Schomberg notes that: 
Responsible Research and Innovation is a transparent, 
interactive process by which societal actors and innovators 
become mutually responsive to each other with a view to the 
(ethical) acceptability, sustainability and societal desirability of 
the innovation process and its marketable products (in order to 
allow a proper embedding of scientific and technological 
advances in our society).195 
A risk-based approach often values expert knowledge and 
authority. With public participation, regulators have better 
knowledge of what laypeople consider important and what 
innovations might be acceptable and socially desirable.196 
Rather than hindering a potentially risky product from being 
marketed, RRI promotes the continuous involvement of various 
stakeholders and considers various perspectives so that a 
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product can be better aligned with societal expectations.197 
Under this framework, regulators are able to address the risks 
of new products in the context of the acceptability of their 
applications and to promote public welfare-oriented responsible 
innovation. 
iii. Adopting RRI to Regulate Genome-Edited Animals Using 
CRISPR-Like Technologies 
Applying the approach that balances precaution and 
innovation to regulate genome-edited animals, the FDA and 
other agencies could evaluate the risks of the use of CRISPR-
Cas9 or other similar technologies in their applications, gather 
inputs from the public regarding their acceptability of the 
product applications, and work collaboratively with developers 
to develop rules that will be aligned with public values and 
expectations. For instance, the FDA might attach conditions to 
approval of new genome-edited animals into the market to 
ensure that the environmental and social benefits outweigh 
harms.198 The FDA could even provide more carrots to 
incentivize innovation that would improve animal welfare, 
environmental, and social benefit—like the hornless breed of 
cattle produced by Recombinetics.199 
Remarkably, on October 30, 2018, the FDA announced a 
new program, the Veterinary Innovation Program (VIP), 
incentivizing animal biotechnological advancement while 
ensuring the safety of animal products.200 Developers of certain 
intentionally altered animals using genome-edited technologies 
that “provide a benefit to human health, animal health, animal 
well-being, or enhanced food production” may participate in the 
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VIP.201 Eligible developers will have the opportunity to interact 
with the Center for Veterinary Medicine review team, receive 
hands-on assistance throughout the review process, and obtain 
additional review process benefits such as alternative data 
options.202 This collaboration between the agency and developers 
can increase the predictability of the regulatory pathway, 
facilitate a lower number of review cycles, and reduce the overall 
time for approval.203 Indeed, the groundbreaking VIP is an 
example of the FDA moving towards a participatory approach 
regulating new biotechnology products. Through eliciting public 
response, working with developers who promote public welfare 
with biotechnologies, and assisting developers in managing the 
risks of their product applications at an earlier stage, the FDA 
is better able to align public values and needs, facilitate 
innovation, and create a targeted, flexible review framework for 
genome-edited animals. 
iv. Setting up a Single Point of Entry 
Coupled with adopting the RRI principles, the White House 
could also update the Coordinated Framework with a “single 
point of entry” for product developers. The National Academies 
of Sciences, Engineering, Medicine proposes in its report the 
following framework: 
Potential product developers and interested parties would 
begin by going to an entry point and providing characteristics of 
the intended product and its use pattern. If the product does not 
fall under a federal statute, the developer would be notified that 
the product is not federally regulated. If the product is regulated, 
the appropriate agency or agencies would be identified for the 
developer. An evaluation of the product’s familiarity to 
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regulatory agencies and its complexity in terms of risk analyses 
as compared to existing biotechnology products would be 
ascertained []. Depending on the product’s familiarity and the 
complexity of its risk analysis, a different set of risk-analysis 
processes would be employed . . . .204 
Under a single point of entry, developers can “evaluate 
whether the intended use of the product is regulated under a 
given statute” instead of window-shopping for regulatory 
approval from different agencies.205 A new office could also be set 
up to facilitate inter-agency consultations where the risks of a 
new product are uncertain and to set future regulatory 
directions for biotechnologies.206 This framework would provide 
an “accessible public face for the regulatory system” for product 
developers, add certainty to the current regulatory system, and 
ensure no new products fall outside of the regulatory 
framework.207 
CONCLUSION 
Existing regulatory structures for genome-edited products 
with technologies like CRISPR-Cas9 cannot keep up with the 
development of biotechnologies. A case in point is the FDA’s 
guidance #187 that attempts to extend its jurisdiction of 
genome-edited animals to intentionally altered genomic DNAs, 
although existing statues do not allow it to do so. The FDA 
erroneously interpreted genomic DNA edited with CRISPR-like 
technologies as a new animal drug under the FD & C Act, which 
was not conceived to cover genome-altered animals when it was 
first passed by Congress. The FDA overlooked the product- and 
risk-based approach set under the current Coordinated 
Framework and adopted a process-based approach that opposes 
the regulatory and scientific consensus. The FDA also 
circumvented the notice-and-comment rulemaking process by 
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instead issuing a guidance document exempted from the APA 
procedural requirements, despite its practically binding legal 
effects. Consequently, this guidance has made the future 
regulatory landscape regarding genome-edited animals 
uncertain and could potentially stifle public confidence and 
scientific innovation that would bring benefits to the 
environment and human health. Though agencies may construe 
the guide-RNA/Cas9 construct inserted into the animal’s 
genome as a new animal drug, a veterinary biologic, or a 
pesticide and extend their oversight of the construct under 
relevant existing statutes, the current structure will handicap 
future biotechnology development. 
More could be done, and a new regulatory approach must be 
introduced. The White House should update the Coordinated 
Framework with a “single point of entry” and encourage the 
agencies to move towards RRI that fosters responsible 
innovation which aligns with public values and expectations. 
The FDA’s proposed VIP is an illustration that an agency could 
move towards a more cautious, nuanced direction when facing 
the unknown and towards a participatory framework that 
balances innovation, oversight, and public interest. 
Last but not least, regulatory agencies must have open 
communication with the public. More open debates are needed 
to clarify policy objectives regarding new biotechnologies. The 
public should be able to participate in discussions that 
determine what constitutes harm, what level of risk is 
acceptable, and who should bear the risk. Agencies must ensure 
that they gather information from all interested parties and 
incorporate their opinions into the respective rulemaking 
processes. Most importantly, agency rules must articulate clear 
standards for any regulatory approach, providing certainty for 
the public and developers of new technologies. 
What is the right regulatory approach towards emerging 
biotechnologies? RRI might be a solution, but the inquiry should 
not stop there. CRISPR-Cas9 democratizes scientific 
advancement, and regulation should not be the impediment to 
scientific progress. While some level of oversight is required, the 
bottom line is that we need the right amount of regulation and 
an approach towards CRISPR-like technologies that will keep 
genome research vibrant, maintain the U.S. competitive edge 
and leadership position, and ensure our present citizens can 
receive the benefits that CRISPR-like technologies provide. 
